Abstract
Antiphospholipid syndrome (APS) is an auto-immune thrombophilia for which anti-thrombotic medication is necessary for long-term management to reduce thrombotic risk or pregnancy morbidity. Choosing the type of pharmacological treatment, i.e. the intensity and duration of anticoagulation, depends on the severity of an individual’s APS and the risk of bleeding. This article reviews the current literature on anticoagulation therapy, provides recommendations on when to initiate therapy, and suggests possible alternatives for optimisation of management.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4:295–306.
Kearon C, Gent M, Hirsh J, et al. A comparison of three month anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Eng J Med. 1999;340:901–7.
Rosove MH, Brewer PM. Anti-phospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Int Med. 1992;117:303–8.
Cervera R, Piette JC, Font J, et al. Antiphospholipid Syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.
• Aguilar-Valenzuela R, Martínez-Martínez LA, Pierangeli SS. A Comprehensive Review of Thrombogenic Mechanisms in APS. Open Autoimmun J. 2012;2:58–66. This review evaluates the current literature on in-vivo and in-vitro studies of the different intracellular events induced by aPL Abs and its thrombogenic effects.
Sciascia S, Lopez-Pedrera C, De Roccatello. Catastrophic antiphospholipid syndrome (CAPS). Best Pract Res Clin Rheumatol. 2012;26:535–41.
Esmon NL, Safa O, Smirnov M, et al. Antiphospholipid antibodies and the protein C pathway. J Autoimmun. 2000;15:221–5.
Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis. 2002;61:46–50.
Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphophospholipid syndrome. J Clin Invest. 2003;112:1644–50.
Giron-Gonzalez JA, del Río EG, Rodríguez C, et al. Anti-phospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31:1560–7.
Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382–91.
Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996;100:530–6.
Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Current Medical Research and Opinion. 2007;23:163–17.
•• Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20:206–18. This important report provides a set of recommendations based on systematic reviews and meta-analysis of all studies concerning management of thrombosis in APS with expert opinions from physicians from different specialities involved in APS.
Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57:1487–95.
Wallace DJ. Antimalarials agents and lupus. Rheum Dis Clin North Am. 1994;20:243–63.
Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice. Circulation. 1997;96:4380–4.
Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum. 1987;30:1435–6.
Wallace DJ, Kinker-Isreli M, Metzger AL, et al. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus. 1993;2:S13–5.
McCarty GA. Hydroxychloroquine (HCQ) treatment in antiphospholipid antibody syndrome (APS): time course of clinical improvement and antiphospholipid antibody (aPL) titer changes over 4 years [abstract]. Arthritis Rheum. 2000;43 Suppl 9:S1061.
Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with anti-phospholipid syndrome. N Eng J Med. 2003;349:1133–8.
Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848–53.
Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin – fourth edition. Br J Haematol. 2011;154:1365–2141.
Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med. 1995;332:993–7.
• Cervera R, Khamashta MA, Shoenfeld Y, et al. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68:1428–32.
Tan BE, Thong BY, Shivananda S, et al. Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort. Lupus. 2009;18:752–8.
Hull RD, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676–81.
Okuma H, Kitagawa Y, Yasuda T, et al. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci. 2009;7:15–8.
Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967–74.
Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969–74.
• Pengo V, Ruiz-Irastorza G, Denas G, et al. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. Autoimmun Rev. 2012;11:577–80. This review evaluates the importance of designing better prospective studies with regard to APS patients and to standardise criteria for APS patients in studies to avoid future conflicting results.
Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–11.
Pattison NS, Chamley LW, McKay EJ, et al. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol. 1993;100:909–13.
Lockwood CJ, Romero R, Feinberg RF, et al. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol. 1989;161:369–73.
Yasuda M, Takakuwa K, Tokunaga A, et al. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995;86:555–9.
Derksen RHWM, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum. 2004;50:1028–39.
Danza A, Ruiz-Irastorza G, Khamashta M. Antiphospholipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol. 2012;26:65–76.
Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992;166:1318–23.
Silver RK, MacGregor SN, Sholl JS, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol. 1993;169:1411–7.
Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol. 1996;35:402–7.
Rai R, Regan L. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment [letter]. Obstet Gynecol. 2002;100:1354.
Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines. Regional anesthesia and pain medicine. 2010;35:64–101.
Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome. Semin Thromb Hemost. 2012;38:339–47.
Pengo V, Denas G, Banzato A, et al. Secondary prevention in thrombotic antiphospholipid syndrome. Lupus. 2012;21:734–5.
Vargas-Hitos JA, Ateka-Barrutia O, Sangle S, et al. Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome. Ann Rheum Dis. 2011;70:1652–4.
Jajoria P, Murthy V, Papalardo E, Romay-Penabad Z, Gleason C, Pierangeli SS. Statins for the Treatment of Antiphospholipid Syndrome? Ann NY Acad Sci. 2009;1173:736–45.
Kumar D, Roubey RA. Use of rituximab in the antiphospholipidsyndrome. Curr Rheumatol Rep. 2010, 12:40–44
Adamson R, Sangle S, Kaul A, et al. Clinical improvement in antiphospholipid syndrome after rituximab therapy. J Clin Rheumatol. 2008;14:359–60.
Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet. 2010;376:1498–509.
Linkins LA, Weitz JI. New anticoagulants. Semin Thromb Hemost. 2003;29:619–31.
Schulman S, Svenungsson E, Granqvist S. Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104:332–8.
Kearon C, Kahn SR, Agnelli G, et al. American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:454S–545S.
•• Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis rheum. 2012;64:504–12. This article investigates the use of a score which all physicians can easily use in common clinical practice to improve the efficiency of identifying severe APS patients to provide the best possible management.
Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Antiphospholipid Syndrome Score. Rheumatology. Rheumatology (Oxford). 2013. doi:10.1093/rheumatology/kes388.
Conflict of Interest
Sinthiya Punnialingam declares that she has no conflict of interest.
Munther A. Khamashta declares that he has no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Antiphospholipid Syndrome
Rights and permissions
About this article
Cite this article
Punnialingam, S., Khamashta, M.A. Duration of Anticoagulation Treatment for Thrombosis in APS: Is It Ever Safe to Stop?. Curr Rheumatol Rep 15, 318 (2013). https://doi.org/10.1007/s11926-013-0318-2
Published:
DOI: https://doi.org/10.1007/s11926-013-0318-2